SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

05 Feb 2025 08:45:03 By NetDania Notify

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

04 Feb 2025 11:22:34 By NetDania Notify

Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease

04 Feb 2025 08:00:05 By Nasdaq GlobeNewswire

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

30 Jan 2025 08:45:48 By NetDania Notify

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

28 Jan 2025 10:23:40 By NetDania Notify

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

27 Jan 2025 09:40:08 By NetDania Notify

Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women

27 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference

26 Nov 2024 16:00:18 By Nasdaq GlobeNewswire

Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference

13 Nov 2024 15:30:46 By Nasdaq GlobeNewswire

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

05 Nov 2024 08:45:03 By NetDania Notify

Supernus Announces Third Quarter 2024 Financial Results

04 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024

31 Oct 2024 15:10:46 By Nasdaq GlobeNewswire

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

30 Oct 2024 14:07:03 By NetDania Notify

Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results

21 Oct 2024 15:25:48 By Nasdaq GlobeNewswire

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

17 Oct 2024 15:05:25 By Nasdaq GlobeNewswire

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder

10 Oct 2024 16:12:14 By Nasdaq GlobeNewswire

Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree

24 Sep 2024 06:30:33 By Nasdaq GlobeNewswire

Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

19 Sep 2024 15:30:44 By Nasdaq GlobeNewswire

Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

28 Aug 2024 15:15:26 By Nasdaq GlobeNewswire

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

19 Aug 2024 06:00:51 By Nasdaq GlobeNewswire